Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab

J Rheumatol. 2005 Dec;32(12):2432-3.

Abstract

Anti-tumor necrosis factor-a (anti-TNF-a) therapy strategies result in significant clinical benefits in patients with rheumatoid arthritis, but with an increased rate of serious infectious diseases. We describe a patient receiving infliximab who developed a primary cutaneous Nocardia otitidiscaviarum infection after a skin injury.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy*
  • Diabetes Mellitus, Type 1 / complications
  • Humans
  • Infliximab
  • Male
  • Nocardia Infections / chemically induced*
  • Nocardia Infections / pathology
  • Skin / injuries
  • Skin Diseases, Bacterial / chemically induced*
  • Skin Diseases, Bacterial / pathology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Wounds and Injuries / microbiology

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab